Protagonist Therapeutics, Inc.
PTGX
$44.04
-$1.23-2.72%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 28.32M | 170.64M | 4.68M | 4.17M | 254.95M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 28.32M | 170.64M | 4.68M | 4.17M | 254.95M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 28.32M | 170.64M | 4.68M | 4.17M | 254.95M |
| SG&A Expenses | 11.74M | 8.95M | 10.16M | 9.44M | 14.91M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 47.63M | 43.86M | 46.13M | 42.96M | 48.64M |
| Operating Income | -19.31M | 126.78M | -41.45M | -38.79M | 206.31M |
| Income Before Tax | -11.66M | 133.66M | -33.63M | -31.29M | 210.67M |
| Income Tax Expenses | -- | 1.99M | -420.00K | -676.00K | 3.33M |
| Earnings from Continuing Operations | -11.66M | 131.67M | -33.21M | -30.62M | 207.34M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -11.66M | 131.67M | -33.21M | -30.62M | 207.34M |
| EBIT | -19.31M | 126.78M | -41.45M | -38.79M | 206.31M |
| EBITDA | -19.07M | 126.90M | -41.22M | -38.55M | 206.55M |
| EPS Basic | -0.19 | 2.11 | -0.54 | -0.50 | 3.41 |
| Normalized Basic EPS | -0.12 | 1.34 | -0.34 | -0.32 | 2.16 |
| EPS Diluted | -0.19 | 1.99 | -0.54 | -0.50 | 3.26 |
| Normalized Diluted EPS | -0.12 | 1.26 | -0.34 | -0.32 | 2.07 |
| Average Basic Shares Outstanding | 62.96M | 62.33M | 61.77M | 61.31M | 60.86M |
| Average Diluted Shares Outstanding | 62.96M | 66.41M | 61.77M | 61.31M | 63.60M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |